Posts by Mourabit Halima

At the 2024 San Antonio Breast Cancer Symposium (SABCS), a study led by Professor Noor Wortelboer from Erasmus University Medical Center in Rotterdam was presented during the "Poster Spotlight 2: Personalizing CDK 4/6 Inhibitor Therapy for Patients with Metastatic Breast Cancer: Survival, QOL, and Biomarkers" session. This research, based on the SONIA trial data, provided an in-depth analysis of health-related quality of life (HRQoL) outcomes in patients using CDK4/6 inhibitors (CDK4/6i) at different treatment lines. The findings offer crucial insights into how CDK4/6i impacts patients’ quality of life and serve as valuable guidance for optimizing treatment strategies in advanced breast cancer. Oncology Frontier invited Dr. Yan Xue from Xi’an International Medical Center Oncology Hospital to interpret and comment on the study's data.

The 47th San Antonio Breast Cancer Symposium (SABCS) recently concluded successfully in San Antonio, USA. SABCS is the world’s largest conference in the field of breast cancer, attracting more than 10,000 registered participants from 102 countries. Over four days, the conference featured thousands of keynote speeches and research abstracts. On December 11, during the second day of the conference, Nobel Laureate in Physiology or Medicine (2019) Professor William Kaelin delivered a highly acclaimed keynote address on the topic of "Tumor Genetics and Targeted Drug Development." Oncology Frontier had the privilege of interviewing Dr. Guojun Zhang from Yunnan Cancer Hospital for a comprehensive review and summary of this lecture.

The de-escalation strategy for axillary management in breast cancer has been a consistent research focus in breast surgery. Last year, the SOUND study explored whether certain low-risk patients undergoing breast-conserving surgery could avoid sentinel lymph node biopsy (SLNB). At the 2024 San Antonio Breast Cancer Symposium (SABCS), the INSEMA study, a similar investigation, was presented. Oncology Frontier invited Dr. Yiding Chen from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of the INSEMA study.

On December 28, 2024, the year-end meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Shanghai. This event brought together renowned experts and promising young talents from across the country to explore new directions in cancer treatment. Oncology Frontier had the honor of interviewing Dr. Biyun Wang, Chair of the conference and a leading expert at Fudan University Shanghai Cancer Center, who shared key highlights of the conference, insights on the development of young oncologists, the achievements of CSCO YOUNG, and future plans.

Dr. Ming Zhao shares key insights on combining local and systemic therapies to improve liver cancer treatment outcomes. Learn how innovative approaches like immunotherapy and targeted treatments are transforming patient care.

The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, brought together leading experts in breast disease to discuss the latest advancements in treatment and management. The conference also focused on consensus guidelines for diagnosing and treating young breast cancer patients, aiming to improve cure rates and rehabilitation outcomes. At the event, Dr. Rui Xu from the Breast Specialty Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine shared cutting-edge findings in breast cancer surgery, offering new perspectives for treatment. In an interview with Oncology Frontier, Professor Xu provided an overview of the latest surgical advancements and developments in integrative medicine for breast cancer.

In 2024, Professor Wu Yilong a luminary in the field of lung cancer and a cornerstone of Oncology Frontier, exemplified unwavering commitment to advancing medical care and education. from leading…